Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Re-Treatment After Discontinuing an EGFR Tyrosine Kinase Inhibitor: Could this be Better than Retreating Beyond Progression?
Article
In my last post, I described the concept of treating with a targeted therapy like an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor at the time of acquired resistance.